Selexis CHO Cells in Suspension-1

Archives 2017

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

DECEMBER 20, 2017
3 min read

Selexis SA and Turgut Pharmaceuticals Advance Partnership with Third Commercial License Agreement

Supports Advancement of Biosimilar to Treat Two Ultra-Rare Diseases

Geneva, Switzerland, and Istanbul, Turkey, 20...

Read More
OCTOBER 4, 2017
4 min read

Selexis SA and Pelican Therapeutics Sign Agreement to Advance Pelican’s Immunotherapy Clinical Programs

Selexis to Develop High-performance Research Cell Banks to Expedite the Manufacturing of Immunotherapy Clinical...

Read More
SEPTEMBER 26, 2017
5 min read

Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs

Second and Third Commercial License Agreements Between the Partners Underscore the Advantages of Selexis’...

Read More
SEPTEMBER 20, 2017
4 min read

Selexis SA, Spinomix SA and the University of Lausanne Publish Novel, High-Throughput Technology Process for Isolation of High Secretion CHO Cell Clones

Paper in Biotechnology and Bioengineering describes faster and more efficient technology for isolation of...

Read More
SEPTEMBER 5, 2017
2 min read

Selexis to Participate at Several Upcoming Industry Conferences

Geneva, Switzerland, 5 SEPTEMBER 2017 – Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More
JUNE 27, 2017
2 min read

Selexis Announces Commercial License Agreement with Takeda for the Development of Fusion Proteins

Geneva, Switzerland, 27 June 2017 – Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More
JUNE 14, 2017
4 min read

JSR Life Sciences Agrees to Acquire Pioneering Cell Line Developer Selexis SA and Integrate Selexis with KBI Biopharma, Inc.

JSR Life Sciences, the life-sciences focused division of JSR Corporation, will offer industry partners best-in-class...

Read More
JUNE 12, 2017
3 min read

Selexis SA and TeneoBio, Inc. Team Up to Advance the Development of UniAbs Targeting Cancer

Geneva, Switzerland and Menlo Park, CA, 12 JUNE 2017 – Selexis SA and TeneoBio, Inc. announced today that they have...

Read More
MAY 30, 2017
2 min read

Merck KGaA, Darmstadt, Germany Licenses Selexis SUREtechnology Platform for Immuno-Oncology Antibody Program

Geneva, Switzerland, 30 MAY 2017 – Selexis SA, a pioneering life sciences company and a global leader in mammalian cell...

Read More
MAY 23, 2017
5 min read

Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist

Geneva, Switzerland, and Nantes, France, 23 May 2017 – Selexis SA and OSE Immunotherapeutics SA (ISIN: FR0012127173;...

Read More
MAY 11, 2017
3 min read

Selexis SA Opens New World-Class Laboratory Facility and Corporate Headquarters in Geneva, Switzerland

Geneva, Switzerland, 12 May 2017 – Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More
MARCH 20, 2017
2 min read

Selexis Announces Launch of Novel Cell Selection Platform Designed to Help Advance Difficult-to-Express Protein Therapeutics to the Clinic

SUREselect can improve the quality of clone selection for cell lines used to manufacture protein therapeutics and...

Read More
MARCH 14, 2017
2 min read

Selexis Announces Participation at Several Upcoming Industry Conferences

Geneva, Switzerland, 14 MARCH 2017 – Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More
FEBRUARY 21, 2017
2 min read

Selexis to Develop Cell Lines for Three Sanofi Biologics Programs Using Selexis SUREtechnology Platform™

Selexis SA Inks Agreement for Applications in Cancer and Infectious Disease Selexis to develop cell lines for three...

Read More
Selexis CHO cells high expressing mAB bispecific antibody
 

Driven by Excellence. Guided by Science.


Connect with us.
From ubiquitous immunoglobulin-based drugs such as monoclonal and bispecific antibodies and Fc Fusions to novel scaffolds and difficult-to-express proteins, Selexis is your partner of choice

 

 

Connect with Us

 

Explore the SUREtechnology Platform™

Selexis Monoclonal Antibodies block

Monoclonal Antibodies

For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.

Learn More
Selexis Difficult-to-Express Proteins block

Difficult-to-Express Proteins

At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.

Learn More
Selexis Bispecific Antibodies block

Bispecific Antibodies

We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.

Learn More
Selexis SA footer Logo

Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.

 

A JSR Life Sciences Company Logo
EN-BEST MEDIUM WORKPLACES_CMYK

Latest News

October 31, 2022

KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer

Read More
September 8, 2022

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

Read More

Copyright© 2023 Selexis SA. All Rights Reserved.